Fate Therapeutics (FATE) FCF Margin (2012 - 2026)
Fate Therapeutics' (FATE) quarterly FCF Margin came in at 2391.15% in Q1 2026, down 27549.0% YoY from N/an in Q1 2025, and down 13.39% on a QoQ basis from 2108.77% in Q4 2025.
Fate Therapeutics (FATE) FCF Margin (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 14 years of FCF Margin data on file, last reported at 2391.15% in Q1 2026.
- Quarterly FCF Margin fell 27549.0% year-over-year to 2391.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1719.98% (down 78924.0% YoY) and the FY2025 annual result came in at 1685.78%, down 78332.0% from the prior year.
- FCF Margin slipped to 2391.15% in Q1 2026, from 2108.77% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 54.37% in Q1 2023 to a low of 3289.6% in Q2 2023.
- A 5-year average of 1342.37% and a median of 1365.82% in 2025 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin slumped 291225 bps — and 2024, when it surged 281073 bps.
- Tracing FATE's FCF Margin over 5 years: stood at 107.21% in 2022, then tumbled by 2272 bps to 2543.08% in 2023, then soared by 41 bps to 1501.24% in 2024, then sank by 40 bps to 2108.77% in 2025, then retreated by 13 bps to 2391.15% in 2026.
- The last three FCF Margin figures came in at 2391.15% (Q1 2026), 2108.77% (Q4 2025), and 1365.82% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | -2,391.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,391.15% |
| Dec 31, 2025 | -2,108.77% |
| Sep 30, 2025 | -1,365.82% |
| Jun 30, 2025 | -1,307.03% |
| Mar 31, 2025 | -2,115.65% |
| Dec 31, 2024 | -1,501.24% |
| Sep 30, 2024 | -953.09% |
| Jun 30, 2024 | -478.87% |
| Mar 31, 2024 | -1,733.19% |
| Dec 31, 2023 | -2,543.08% |
| Sep 30, 2023 | -1,699.28% |
| Jun 30, 2023 | -3,289.60% |
| Mar 31, 2023 | -54.37% |
| Dec 31, 2022 | -107.21% |
| Sep 30, 2022 | -425.36% |
| Jun 30, 2022 | -377.35% |
| Mar 31, 2022 | -369.23% |
| Dec 31, 2021 | -687.65% |
| Sep 30, 2021 | -136.36% |
| Jun 30, 2021 | -351.04% |